Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Lymphoid 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 142Stomach Neoplasms 104Carcinoma, Non-Small-Cell Lung 87Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Melanoma 59Esophageal Neoplasms 57Ovarian Neoplasms 50Squamous Cell Carcinoma of Head and Neck 49Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasms 43Carcinoma, Renal Cell 43Triple Negative Breast Neoplasms 39Neoplasm Metastasis 37Lung Neoplasms 36Breast Neoplasms 36Uterine Cervical Neoplasms 35Cholangiocarcinoma 35Esophageal Squamous Cell Carcinoma 33Head and Neck Neoplasms 29Endometrial Neoplasms 29Biliary Tract Neoplasms 26Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Colonic Neoplasms 23Small Cell Lung Carcinoma 20Prostatic Neoplasms 17Liver Neoplasms 17Adenocarcinoma Of Esophagus 15Adenocarcinoma 15

Interventions

pembrolizumab 1Radiation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma, Myxoid × pembrolizumab × Gastrointestinal × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡